N Lytvynenko1, S Cherenko1, Y Feschenko1, M Pogrebna1, Y Senko1, A Barbova1, M Manzi2, O Denisiuk3, A Ramsay4, R Zachariah2. 1. F G Yanovsky National Academy of Medical Sciences of Ukraine, Kiev, Ukraine. 2. Brussels Operational Center, Médecins Sans Frontières (MSF), MSF Luxembourg, Luxembourg. 3. Global AIDS Alliance, Kiev, Ukraine. 4. Special Programme for Research and Training in Tropical Diseases, World Health Organization, Geneva, Switzerland ; University of St Andrews Medical School, North Haugh, Scotland, United Kingdom.
Abstract
SETTING: A tertiary care facility in Ukraine, a high multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) burden country. OBJECTIVES: To assess the management and treatment outcomes of MDR, pre-XDR-TB and XDR-TB. DESIGN: Cohort study using programme data, 2006-2011. RESULTS: Of 484 individuals with drug-resistant TB, 217 (45%) had MDR-, 153 (32%) pre-XDR- and 114 (24%) XDR-TB. Of all resistant types completing the intensive phase of treatment, 322 (67%) were alive and had culture converted. This included 157 (72%) with MDR- and 61 (54%) with XDR-TB. At the end of the continuation phase of treatment, 106 (22%) had treatment success and 378 (78%) had unfavourable outcomes, including 110 (23%) failures, 21 (4%) deaths, 71 (15%) losses to follow-up and 176 (36%) with an unknown outcome. This was associated with more than one lung cavity being affected, a history of treatment with second-line anti-tuberculosis drugs, poor adherence and XDR-TB. A total of 226 (47%) patients reported at least one adverse drug reaction, the most common being gastrointestinal and vestibular toxicity. CONCLUSION: Outcomes of MDR- and XDR-TB were satisfactory in the intensive phase; however, this was not sustained during the ambulatory period. If we are to do better, urgent measures are needed to improve ambulatory management, including making safer, shorter and more effective drug regimens available.
SETTING: A tertiary care facility in Ukraine, a high multi- and extensively drug-resistant tuberculosis (MDR/XDR-TB) burden country. OBJECTIVES: To assess the management and treatment outcomes of MDR, pre-XDR-TB and XDR-TB. DESIGN: Cohort study using programme data, 2006-2011. RESULTS: Of 484 individuals with drug-resistant TB, 217 (45%) had MDR-, 153 (32%) pre-XDR- and 114 (24%) XDR-TB. Of all resistant types completing the intensive phase of treatment, 322 (67%) were alive and had culture converted. This included 157 (72%) with MDR- and 61 (54%) with XDR-TB. At the end of the continuation phase of treatment, 106 (22%) had treatment success and 378 (78%) had unfavourable outcomes, including 110 (23%) failures, 21 (4%) deaths, 71 (15%) losses to follow-up and 176 (36%) with an unknown outcome. This was associated with more than one lung cavity being affected, a history of treatment with second-line anti-tuberculosis drugs, poor adherence and XDR-TB. A total of 226 (47%) patients reported at least one adverse drug reaction, the most common being gastrointestinal and vestibular toxicity. CONCLUSION: Outcomes of MDR- and XDR-TB were satisfactory in the intensive phase; however, this was not sustained during the ambulatory period. If we are to do better, urgent measures are needed to improve ambulatory management, including making safer, shorter and more effective drug regimens available.
Entities:
Keywords:
MDR-TB drug regimens; SORT IT; decentralisation; operational research
Authors: J C M Brust; N S Shah; M Scott; K Chaiyachati; M Lygizos; T L van der Merwe; S Bamber; Z Radebe; M Loveday; A P Moll; B Margot; U G Lalloo; G H Friedland; N R Gandhi Journal: Int J Tuberc Lung Dis Date: 2012-06-05 Impact factor: 2.373
Authors: Armand Van Deun; Aung Kya Jai Maug; Md Abdul Hamid Salim; Pankaj Kumar Das; Mihir Ranjan Sarker; Paul Daru; Hans L Rieder Journal: Am J Respir Crit Care Med Date: 2010-05-04 Impact factor: 21.405
Authors: M Edginton; D Enarson; R Zachariah; T Reid; S Satyanarayana; K Bissell; S G Hinderaker; T Harries Journal: Public Health Action Date: 2012-03-21
Authors: W M Jakubowiak; E M Bogorodskaya; S E Borisov; E S Borisov; I D Danilova; D I Danilova; E V Kourbatova; E K Kourbatova Journal: Int J Tuberc Lung Dis Date: 2007-01 Impact factor: 2.373
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Lancet Date: 2007-10-20 Impact factor: 79.321
Authors: Ibrahim Abubakar; Matteo Zignol; Dennis Falzon; Mario Raviglione; Lucica Ditiu; Susan Masham; Ifedayo Adetifa; Nathan Ford; Helen Cox; Stephen D Lawn; Ben J Marais; Timothy D McHugh; Peter Mwaba; Matthew Bates; Marc Lipman; Lynn Zijenah; Simon Logan; Ruth McNerney; Adam Zumla; Krishna Sarda; Payam Nahid; Michael Hoelscher; Michel Pletschette; Ziad A Memish; Peter Kim; Richard Hafner; Stewart Cole; Giovanni Battista Migliori; Markus Maeurer; Marco Schito; Alimuddin Zumla Journal: Lancet Infect Dis Date: 2013-03-24 Impact factor: 25.071
Authors: W M Jakubowiak; E M Bogorodskaya; S E Borisov; I D Danilova; O B Lomakina; E V Kourbatova Journal: Tuberculosis (Edinb) Date: 2008-05-23 Impact factor: 3.131
Authors: Frank A Post; Daniel Grint; Anne Marie Werlinrud; Alexander Panteleev; Vieja Riekstina; Evgeniy A Malashenkov; Alena Skrahina; Dan Duiculescu; Daria Podlekareva; Igor Karpov; Vasiliy Bondarenko; Nelly Chentsova; Jens Lundgren; Amanda Mocroft; Ole Kirk; Jose M Miro Journal: J Infect Date: 2013-11-16 Impact factor: 6.072
Authors: Petros Isaakidis; Bhanumati Varghese; Homa Mansoor; Helen S Cox; Joanna Ladomirska; Peter Saranchuk; Esdras Da Silva; Samsuddin Khan; Roma Paryani; Zarir Udwadia; Giovanni Battista Migliori; Giovanni Sotgiu; Tony Reid Journal: PLoS One Date: 2012-07-11 Impact factor: 3.240
Authors: L T Daum; O S Konstantynovska; O S Solodiankin; O O Liashenko; P I Poteiko; V I Bolotin; I I Hrek; A V Rohozhyn; J D Rodriguez; G W Fischer; J P Chambers; A P Gerilovych Journal: J Clin Microbiol Date: 2018-05-25 Impact factor: 5.948
Authors: Joel Philip Samuels; Aashna Sood; Jonathon R Campbell; Faiz Ahmad Khan; James Cameron Johnston Journal: Sci Rep Date: 2018-03-21 Impact factor: 4.379
Authors: Silvia Shinpei Chiang; Yana Sheremeta; Rachel Sophie Padilla; Helen Elizabeth Jenkins; Charles Robert Horsburgh; Vasyl Petrenko; Natasha Renee Rybak Journal: J Epidemiol Glob Health Date: 2019-03